Oncoinvent ASA Cash Flow Conversion Efficiency
Oncoinvent ASA cash flow conversion efficiency. Based on the latest financial reports, Oncoinvent ASA (ONCIN) has a cash flow conversion efficiency ratio of -1.103x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-73.90 Million ≈ $-7.78 Million USD) by net assets (Nkr67.00 Million ≈ $7.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oncoinvent ASA (2021–2025)
Cash flow conversion efficiency of Oncoinvent ASA from 2021 to 2025. This chart illustrates how Oncoinvent ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ONCIN share price today for real-time trading data and today's change.
Oncoinvent ASA Cash Flow Conversion Ratio Explained
Oncoinvent ASA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oncoinvent ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncoinvent ASA ranked by their cash flow conversion efficiency. Also see Oncoinvent ASA market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shaftesbury Capital PLC
LSE:SHC
|
0.002x |
|
Daedong Gear Co. Ltd
KQ:008830
|
0.067x |
|
AtlasClear Holdings, Inc.
NYSE MKT:ATCH
|
-0.081x |
|
Innovative Solutions Ecosystem SA
MC:ISE
|
0.005x |
|
Impresa - Sociedade Gestora de Participações Sociais S.A
LS:IPR
|
-0.174x |
|
NextNRG Inc.
NASDAQ:NXXT
|
0.113x |
|
Eternit S.A
SA:ETER3
|
-0.014x |
|
AKKO Invest Nyrt
BUD:AKKO
|
0.073x |
Annual Cash Flow Conversion Efficiency for Oncoinvent ASA (2021–2025)
The table below shows the annual cash flow conversion efficiency of Oncoinvent ASA from 2021 to 2025. Review ONCIN financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr146.32 Million ≈ $15.40 Million |
Nkr-131.19 Million ≈ $-13.80 Million |
-0.897x | +36.62% |
| 2024-12-31 | Nkr108.33 Million ≈ $11.40 Million |
Nkr-153.24 Million ≈ $-16.13 Million |
-1.415x | -30.56% |
| 2023-12-31 | Nkr127.48 Million ≈ $13.41 Million |
Nkr-138.11 Million ≈ $-14.53 Million |
-1.083x | +66.73% |
| 2022-12-31 | Nkr88.50 Million ≈ $9.31 Million |
Nkr-288.23 Million ≈ $-30.33 Million |
-3.257x | -312.75% |
| 2021-12-31 | Nkr384.43 Million ≈ $40.45 Million |
Nkr-303.34 Million ≈ $-31.92 Million |
-0.789x | -- |
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.